Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Indian small-cap stocks recover losses since the US-Iran war, outpacing large-cap stocks

Indian small-cap stocks recover losses since the US-Iran war, outpacing large-cap stocks

金十金十2026/04/15 07:08
Show original
Golden Ten Data reported on April 15 that Indian small-cap stocks have shown remarkable performance, successfully erasing losses caused by the Israel-Iran conflict, while large-cap stocks have yet to achieve the same. On Wednesday, the Indian NIFTY Smallcap 250 Index rose by over 2%, recouping more than 10% of the drop since the outbreak of the conflict. Meanwhile, the Indian NIFTY 50 Index still lags behind in recovering losses, remaining about 4% below its previous level. Small-cap stocks are typically seen as a barometer of market sentiment. After underperforming large-cap stocks for over a year, they have once again attracted attention. In March, inflows into Indian small-cap mutual funds increased by 61% compared to the previous month, reaching 63 billion Indian rupees, as retail investors gobbled up shares that had fallen due to the conflict.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Yen appreciation and global bond slump lead Japan GPIF to first loss in six quarters, with almost no asset allocation adjustment

According to the latest quarterly report from Japan’s Government Pension Investment Fund (GPIF), its asset allocation remained almost unchanged from its model portfolio for the three months ending in late September. However, the fund recorded a 1.7% quarterly loss during this period—the first loss in six quarters—due to a global slump in bond prices and the appreciation of the yen.

智通财经•2026/11/06 08:27

GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions

Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.

智通财经•2026/11/06 07:56